HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer

Cancer Gene Therapy

Volumn 22, Issue 12, 2015, Pages 581-590

  Muralidharan, R ^a,b   Panneerselvam, J ^a,b   Chen, A ^b   Zhao, Y D ^b   Munshi, A ^a,b   Ramesh, R ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CHEMOKINE RECEPTOR CXCR4; ELAV LIKE PROTEIN 1; FOLATE RECEPTOR 1; GELATINASE A; GELATINASE B; NANOPARTICLE; PLERIXAFOR; PROTEIN KINASE B; PROTEIN P27; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CXCR4 PROTEIN, HUMAN; ELAVL1 PROTEIN, HUMAN; HETEROCYCLIC COMPOUND;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; NCI-H1299 CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR INVASION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY;

ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DOWN-REGULATION; ELAV-LIKE PROTEIN 1; HETEROCYCLIC COMPOUNDS; HUMANS; LUNG NEOPLASMS; NANOPARTICLES; NEOPLASM INVASIVENESS; RECEPTORS, CXCR4; RNA, SMALL INTERFERING;

EID: 84945162440     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2015.55     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Liu L, Zhao E, Li C, Huang L, Xiao L, Cheng L et al. TRIM28, a new molecular marker predicting metastasis and survival in early-stage non-small cell lung cancer. Cancer Epidemiol 2013; 37: 71-78.
3. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011; 331: 1559-1564.
4. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP, Streiter RM et al. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 2003; 167: 1676-1686.
5. Vandercappellen J, Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett 2008; 267: 226-244.
6. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R et al. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 2005; 11: 8273-8280.
7. Oonakahara K, Matsuyama W, Higashimoto I, Kawabata M, Arimura K, Osame M et al. Stromal-derived factor-1alpha/CXCL12-CXCR 4 axis is involved in the dissemination of NSCLC cells into pleural space. Am J Respir Cell Mol Biol 2004; 30: 671-677.
8. Minamiya Y, Saito H, Takahashi N, Ito M, Imai K, Ono T et al. Expression of the chemokine receptor CXCR4 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2010; 68: 466-471.
9. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA et al. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg 2009; 137: 615-621.
10. Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E et al. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol 2008; 39: 1751-1755.
11. Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D et al. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer. J Thorac Oncol 2011; 6: 1169-1178.
12. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931.
13. D'Alterio C, Barbieri A, Portella L, Palma G, Polimeno M, Riccio A et al. Inhibition of stromal CXCR4 impairs development of lung metastases. Cancer Immunol Immunother 2012; 61: 1713-1720.
14. Uchida D, Onoue T, Kuribayashi N, Tomizuka Y, Tamatani T, Nagai H et al. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur J Cancer 2011; 147: 452-459.
15. Ramsey DM, McAlpine SR. Halting metastasis through CXCR4 inhibition. Bioorg Med Chem Lett 2013; 23: 20-25.
16. Uy GL, Rettig MP, Motabi IH, McFarland K, Trinkaus KM, Hladnik LM et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917-3924.
17. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
18. Peled A, Wald O, Burger J. Development of novel CXCR4-based therapeutics. Expert Opin Investig Drugs 2012; 21: 341-353.
19. Srikantan S, Gorospe M. HuR function in disease. Front Biosci (Landmark Ed) 2012; 17: 189-205.
20. Abdelmohsen K, Gorospe M. Post transcriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 2010; 1: 214-229.
21. Wang J, Guo Y, Chu H, Guan Y, Ji Bi, Wang B. Multiple functions of the RNAbinding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci 2013; 14: 10015-10041.
22. López de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2: 11-13.
23. Wang WG, Caldwell MC, Lin SK, Furneaux H, Gorospe M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J 2000; 19: 2340-2350.
24. Lauriola L, Granone P, Ramella S, Lanza P, Ranelletti FO. Expression of the RNAbinding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol Histopathol 2012; 27: 617-626.
25. Denkert C, Koch I, von Keyserlingk N, Noske A, Niesporek S, Dietel M et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 2006; 19: 1261-1269.
26. Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A, Buckendahl AC et al. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 2008; 32: 341-347.
27. Wang D, Wang M, Hu C, Shuang T, Zhou Y, Yan X. Expression of the ELAV-like protein HuR in the cytoplasm is associated with endometrial carcinoma progression. Tumour Biol 2014; 35: 11939-11947.
28. Al-Souhibani N, Al-Ghamdi M, Al-Ahmadi W, Khabar KS. Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis 2014; 35: 1983-1992.
29. Ramesh R, Saeki T, Templeton NS, Ji L, Stephens LC, Ito I et al. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector. Mol Ther 2001; 3: 337-350.
30. Began G, Ito I, Branch CD, Clifton Stephens L, Roth JA, Ramesh R. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms, and strategies to suppress nanoparticle-mediated inflammatory response. Technol Cancer Res Treat 2004; 3: 647-657.
31. Babu A, Wang Q, Muralidharan R, Shanker M, Munshi A, Ramesh R. Chitosan coated poly(lactic acid) polymeric nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm 2014; 11: 2720-2733.
32. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther 2000; 7: 2051-2057.
33. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003; 63: 5105-5113.
34. Panneerselvam J, Shanker M, Jin J, Branch CD, Muralidharan R, Zhao DY et al. Phosphorylation of interleukin (IL)-24 is required for mediating its anti-cancer activity. Oncotarget 2015; 18: 16271-16286.
35. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S. Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther 2004; 9: 510-518.
36. Panneerselvam J, Jin J, Shanker M, Lauderdale J, Bates J, Wang Q et al. Disruption of the CXCR-4/SDF axis by interleukin (IL)-24 reduces tumor cell migration and invasion in lung cancer cells. PLoS One 2015; 10: e0122439.
37. Liu J, Ping W, Zu Y, Sun W. Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer. Int J Clin Exp Pathol 2014; 7: 6040-6047.
38. Pritchard SC, Nicolson MC, Lloret C, McKay JA, Ross VG, Kerr KM et al. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 2001; 8: 421-424.
39. Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004; 18: 1240-1242.
40. Chinni SR, Sivalogan S, Dong Z, Filho JC, Deng X, Bonfil RD et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate 2006; 66: 32-48.
41. Muralidharan R, Babu A, Basalingappa K, Mehta M, Munshi A, Ramesh R. Designing of tumor-targeted HuRsiRNA nanoparticle as a therapeutic for lung cancer. In: Gandhi V, Mehta K, Grover RK, Pathak S, Aggarwal BB (eds). Multitargeted Approach to the Treatment of Cancer. Springer International Publishing: Switzerland, pp 277-294, 2015.
42. Babu A, Amreddy N, Muralidharan R, Munshi A, Ramesh R. Nanoparticle-mediated siRNA delivery for lung cancer treatment. In: Naik J (ed). Nano Based Drug Delivery. IAPC Publishing: Croatia, pp 195-215, 2015.
43. Akool El-S, Kleinert H, Hamada FM, Abdelwahab MH, Förstermann U, Pfeilschifter J et al. Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003; 23: 4901-4916.
44. Chen H, Xu X, Teng J, Cheng S, Bunjhoo H, Cao Y et al. CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2. Int J Clin Exp Pathol 2015; 8: 6700-6777.